Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer.
作者信息
Ingle James N
机构信息
Mayo Clinic, Rochester, MN 55905, USA.
出版信息
Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S17. doi: 10.1186/bcr2177. Epub 2008 Dec 18.
Abstract
摘要
相似文献
1
Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer.
Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S17. doi: 10.1186/bcr2177. Epub 2008 Dec 18.
2
Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.
Anticancer Agents Med Chem. 2017;17(13):1805-1813. doi: 10.2174/1871521409666170412124226.
3
Pharmacogenomics of tamoxifen and aromatase inhibitors.
Cancer. 2008 Feb 1;112(3 Suppl):695-699. doi: 10.1002/cncr.23192.
4
Postmenopausal breast cancer: a best endocrine strategy?
Lancet. 2015 Oct 3;386(10001):1317-1319. doi: 10.1016/S0140-6736(15)61206-5. Epub 2015 Jul 23.
5
6
Pharmacogenomics of endocrine therapy in breast cancer.
Adv Exp Med Biol. 2008;630:220-31. doi: 10.1007/978-0-387-78818-0_14.
7
Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
J Clin Oncol. 2005 Aug 1;23(22):4850-2. doi: 10.1200/JCO.2005.03.904. Epub 2005 Jul 11.
8
By the way, doctor. Should I switch from tamoxifen to an aromatase inhibitor?
Harv Womens Health Watch. 2007 Jun;14(10):8.
9
Adherence with adjuvant hormonal therapy for breast cancer.
Ann Oncol. 2009 Mar;20(3):401-2. doi: 10.1093/annonc/mdp039.
10
Aromatase inhibitors: what is the true cost?
Intern Med J. 2011 Feb;41(2):139-40. doi: 10.1111/j.1445-5994.2010.02422.x.
引用本文的文献
1
Proteomics and its applications in breast cancer.
Am J Cancer Res. 2021 Sep 15;11(9):4006-4049. eCollection 2021.
2
Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients.
Breast Cancer (Dove Med Press). 2013 Aug 22;5:73-8. doi: 10.2147/BCTT.S47172. eCollection 2013.
3
Integrative Analysis of Response to Tamoxifen Treatment in ER-Positive Breast Cancer Using GWAS Information and Transcription Profiling.
Breast Cancer (Auckl). 2012;6:47-66. doi: 10.4137/BCBCR.S8652. Epub 2012 Feb 20.
4
Understanding the mechanisms of aromatase inhibitor resistance.
Breast Cancer Res. 2012 Jan 19;14(1):201. doi: 10.1186/bcr2931.
5
Letrozole: a review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer.
Drugs. 2009 Aug 20;69(12):1681-705. doi: 10.2165/10482340-000000000-00000.
6
Identification and mechanisms of endocrine resistance.
Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S19. doi: 10.1186/bcr2179. Epub 2008 Dec 18.
7
Introduction to sessions on 'Endocrine therapy: where have we come from, where are we at and where are we going to'?
Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S15. doi: 10.1186/bcr2175. Epub 2008 Dec 18.
本文引用的文献
1
Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.
Clin Cancer Res. 2008 Sep 15;14(18):5913-8. doi: 10.1158/1078-0432.CCR-07-5235.
2
Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.
Ann Oncol. 2008 Aug;19(8):1423-1429. doi: 10.1093/annonc/mdn155. Epub 2008 Apr 11.
3
Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.
Cancer Sci. 2008 May;99(5):995-9. doi: 10.1111/j.1349-7006.2008.00780.x. Epub 2008 Feb 24.
4
Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.
J Clin Oncol. 2008 Feb 1;26(4):556-62. doi: 10.1200/JCO.2007.11.5451. Epub 2008 Jan 7.
5
Pharmacogenomics of tamoxifen and aromatase inhibitors.
Cancer. 2008 Feb 1;112(3 Suppl):695-699. doi: 10.1002/cncr.23192.
6
Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.
J Clin Oncol. 2008 Feb 1;26(4):549-55. doi: 10.1200/JCO.2006.10.1022. Epub 2007 Dec 10.
7
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
J Clin Oncol. 2007 Nov 20;25(33):5187-93. doi: 10.1200/JCO.2007.12.2705.
8
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Breast Cancer Res. 2007;9(1):R7. doi: 10.1186/bcr1640.
9
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Breast Cancer Res Treat. 2007 Jan;101(1):113-21. doi: 10.1007/s10549-006-9428-0. Epub 2006 Nov 18.
10
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Clin Pharmacol Ther. 2006 Jul;80(1):61-74. doi: 10.1016/j.clpt.2006.03.013.
Zotero 插件